Stablecoin Development Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Kazley

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

We Think NovaBay Pharmaceuticals (NYSEMKT:NBY) Can Afford To Drive Business Growth

Mar 29

CEO

Michael Kazley (34 yo)

less than a year

Görev süresi

Mr. Michael Kazley is Chairman of Stablecoin Development Corporation (formerly known as NovaBay Pharmaceuticals, Inc.) from October 2025. Mr. Kazley is Director of Stablecoin Development Corporation (forme...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Kazley	Chairman & CEO	less than a year	Veri yok	Veri yok
Paul Freiman	Independent Director	23.9yrs	US$111.70k	0.00077% $ 385.4
Yenyou Zheng	Independent Director	6.6yrs	US$107.20k	0.00071% $ 355.4
Pedram Hamrah	Member of Ophthalmic Advisory Board	10.5yrs	Veri yok	Veri yok
Swan Sit	Independent Director	6.3yrs	US$92.70k	0.00071% $ 355.4
Komal Thakore	Member of the Optometry Advisory Board	5.4yrs	Veri yok	Veri yok
Amr Kouchouk	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok
John Aljian	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok
Laura Periman	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok
Milap Mehta	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok
Melanie Bennett-Sims	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok
Michelle Rhee	Member of the Ophthalmic Advisory Board	5.4yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SDEV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/07 15:16
Gün Sonu Hisse Fiyatı	2026/04/07 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Stablecoin Development Corporation 8 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Pooya Hemami	Desjardins Securities Inc.
Christian Glennie	Edison Investment Research

Stablecoin Development Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025

Novabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025

Insufficient new directors

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

Recent updates

New major risk - Negative shareholders equity

New minor risk - Market cap size

Now 33% undervalued

NovaBay Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Now 50% overvalued after recent price rise

New major risk - Shareholder dilution

Insufficient new directors

New major risk - Market cap size

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Oct 16, 2025

NovaBay Pharmaceuticals, Inc. announces special dividend, payable on September 29, 2025

Novabay Pharmaceuticals, Inc. Chief Executive Officer Changes, Effective August 19, 2025

New major risk - Share price stability

NovaBay Pharmaceuticals, Inc. announced that it expects to receive $6 million in funding

Insufficient new directors

NovaBay Pharmaceuticals, Inc. announced delayed annual 10-K filing

Consensus EPS estimates fall by 131%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $11.5 million.

Consensus revenue estimates decrease by 15%, EPS upgraded

New major risk - Negative shareholders equity

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

NovaBay Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Novabay Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

NYSE American Accepts NovaBay Pharmaceuticals Plan of Compliance

No longer forecast to breakeven

NovaBay Pharmaceuticals Provides Non-Compliance Update

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

NovaBay Pharmaceuticals, Inc., Annual General Meeting, May 28, 2024

Consensus EPS estimates upgraded to US$0.27 loss, revenue downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY).

New Age Investments LLC entered into a Membership Unit Purchase Agreement to acquire DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc. (NYSEAM:NBY) for $1.07 million.

New minor risk - Share price stability

NovaBay Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Novabay Pharmaceuticals, Inc. Announces Commercial Launch of Avenova Allograft

Consensus EPS estimates fall by 56%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profitability

NovaBay Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Novabay Pharmaceuticals, Inc. Announces Audrey Kunin to Retire and Resign from Her Position as Chief Product Officer Effective as of November 5, 2023

Novabay Pharmaceuticals, Inc. Approves to Elect Mijia (Bob) Wu as Director

NovaBay Pharmaceuticals, Inc. Announces DERMAdoctor's KP Duty Lotion and Scrub Ultra Duo Set for Dry, Rough, Bumpy Skin to Be Featured on QVC at a Special Price

NovaBay Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2023

Consensus revenue estimates increase by 20%

No longer forecast to breakeven

NovaBay Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NovaBay Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 23, 2023

Novabay Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Consensus EPS estimates fall by 57%

Price target decreased to US$39.88

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

NovaBay Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Novabay Pharmaceuticals, Inc. Announces Newest Addition to the Dermadoctor Picture Porefect Collection 15% Niacinamide Pore Minimizing Serum

NovaBay Pharmaceuticals, Inc.’ Avenova and DERMAdoctor Products to be Featured During the October 11-12 Amazon Prime Early Access Sale

NovaBay Pharmaceuticals Receives NYSE American Notice Regarding Low Share Price

Consensus EPS estimates fall by 13%

Price target decreased to US$2.80

NovaBay Pharmaceuticals, Inc. announced that it expects to receive $3.25 million in funding

Consensus EPS estimates fall by 14%

Price target decreased to US$2.98

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

NovaBay Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Novabay Pharmaceuticals, Inc. Announces Availability of Select Dermadoctor Products

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind